Zolpidem
Title: Zolpidem
CAS Registry Number: 82626-48-0
CAS Name: N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide
Additional Names: N,N,6-trimethyl-2-p-tolylimidazo[1,2-a]pyridine-3-acetamide
Manufacturers' Codes: SL-80.0750
Molecular Formula: C19H21N3O
Molecular Weight: 307.39
Percent Composition: C 74.24%, H 6.89%, N 13.67%, O 5.20%
Literature References: Selective non-benzodiazepine GABAA receptor agonist. Prepn: J. P. Kaplan, P. George, EP 50563; eidem, US 4382938 (1982, 1983 both to Synthelabo). Neuropharmacology: S. Arbilla et al., Arch. Pharmacol. 330, 248 (1985); H. Depoortere et al., J. Pharmacol. Exp. Ther. 237, 649 (1986). Neurochemical profile: B. Scatton et al., ibid. 659. Binding study in rat brain: S. Arbilla et al., Eur. J. Pharmacol. 130, 257 (1986). HPLC determn in plasma: P. Guinebault et al., J. Chromatogr. 383, 206 (1986). Clinical evaluation of hypnotic activity: A. N. Nicholson, P. A. Pascoe, Br. J. Clin. Pharmacol. 21, 205 (1986). Evaluation as pre-anesthetic medication: J. N. Cashman et al., ibid. 24, 85 (1987). Review of pharmacology and therapeutic potential: H. D. Langtry, P. Benfield, Drugs 40, 291-313 (1990).
Properties: mp 196°. pKa 6.2.
Melting point: mp 196°
pKa: pKa 6.2
 
Derivative Type: L-(+)-Hemitartrate
CAS Registry Number: 99294-93-6
Manufacturers' Codes: SL-80.0750-23N
Trademarks: Ambien (Sanofi-Aventis); Ivadal (Sanofi-Aventis); Niotal (Sanofi-Synthelabo); Stilnoct (Sanofi-Aventis); Stilnox (Sanofi-Synthelabo)
Molecular Formula: (C19H21N3O)2.C4H6O6
Molecular Weight: 764.87
Percent Composition: C 65.95%, H 6.33%, N 10.99%, O 16.73%
Properties: Soly in water (20°): 23 mg/ml. Sparingly sol in alcohol, propylene glycol.
 
NOTE: This is a controlled substance (depressant): 21 CFR, 1308.14.
Therap-Cat: Sedative, hypnotic.
Keywords: Sedative/Hypnotic; Imidazopyridines.

Others monographs:
Gallium OxideBismark Brown RSaponarinp-Anol
IpronidazoleNorgesteroneNerolidolSpinulosin
OxytocinNapropamidePovidone-IodineSodium Nitrate
Lucanthone HydrochlorideDMCDimefoxDetaxtran
©2016 DrugLead US FDA&EMEA